CRISPR-Corrected iPSC Keratinocytes for RDEB Wound Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for recessive dystrophic epidermolysis bullosa (RDEB) are limited to supportive care, with no approved treatments to correct the underlying genetic defect, leading to chronic wounds, pain, and increased risk of invasive squamous cell carcinoma.
Innovation Solution
Integration-free, xeno-free, feeder-free production of CRISPR-corrected induced pluripotent stem cells (iPSCs) from fibroblasts, which are differentiated into genetically corrected keratinocyte stem cells (iKCs) for grafting onto wounds to produce functional collagen VII, promoting wound closure and tissue repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If CRISPR-Cas9 genome editing is used to correct COL7A1 mutations in RDEB patients, then genetic correction efficiency is improved, but the risk of off-target effects and genomic instability increases
Solution Approach 1:
The patent uses a homology-directed repair (HDR) template as an intermediary to guide precise genome editing. The HDR template contains the correct COL7A1 sequence and directs the repair of CRISPR-induced double-strand breaks at the mutation site, ensuring accurate correction while minimizing off-target effects through homology-based recognition.
Solution Approach 2:
The patent employs optimized CRISPR-Cas9 parameters including guide RNA design, Cas9 protein concentration, and HDR template composition to maximize on-target editing efficiency while minimizing off-target effects. The system uses a ratio of 1:5 to 1:20 of HDR template to Cas9 protein to control the balance between cutting efficiency and repair accuracy.
2Productivity
If multiple cell culture steps and feeder layers are used in iPSC production, then cell expansion and differentiation efficiency are improved, but the risk of contamination and immunogenicity increases
Solution Approach 1:
The patent extracts and eliminates feeder layers from the cell culture system, replacing them with feeder-free culture conditions. This removes the source of contamination and immunogenicity associated with animal-derived feeder cells while maintaining cell expansion efficiency through optimized culture media and growth factors.
Solution Approach 2:
The patent uses disposable, xeno-free culture vessels and media components that eliminate the need for reusable equipment requiring sterilization and reduce contamination risks. The system employs single-use bioreactors and pre-prepared growth media that contain all necessary nutrients without animal-derived components.
3Stability of the object's composition
If integration-based methods are used for genetic correction, then stability of correction is improved, but the risk of insertional mutagenesis and tumorigenesis increases
Solution Approach 1:
The patent converts the potential harm of genomic integration into a benefit by using homology-directed repair to precisely integrate the corrected COL7A1 sequence at the exact location of the original gene. This ensures stable correction while avoiding random insertional mutagenesis, as the integration occurs only at the intended target site through homology-based recognition.
Solution Approach 2:
The patent applies local quality by ensuring that genetic correction is confined to the specific COL7A1 locus rather than random genome-wide integration. The HDR template contains homology arms that direct integration only at the matching sequence in the genome, providing localized and precise correction without affecting other genomic regions.
4Ease of manufacture
If conventional wound care treatments are used for RDEB patients, then immediate wound coverage is improved, but the long-term risk of infection and squamous cell carcinoma increases
Solution Approach 1:
The patent applies preliminary action by genetically correcting COL7A1 mutations in patient-derived iPSCs before differentiation and transplantation. This pre-correction ensures that the transplanted keratinocytes produce functional type VII collagen from the outset, providing long-term protection against wound complications rather than merely covering wounds temporarily.
Solution Approach 2:
The patent enables self-service by creating autologous, genetically corrected keratinocytes that inherently produce functional type VII collagen and anchoring fibrils. These corrected cells autonomously provide wound coverage and protection without requiring continuous external intervention, reducing long-term infection risk and eliminating the need for ongoing supportive care.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the production of functional human stratified epidermal grafts that adhere tightly to the dermis, produce type VII collagen, and demonstrate similar gene expression to donor keratinocytes, offering a potential long-term solution for RDEB by enhancing wound closure and reducing the risk of squamous cell carcinoma.
Implementation Method 1
CRISPR-Cas9-mediated genome editing requires only a short single-guide RNA (sgRNA) to guide site-specific DNA recognition and cleavage
Implementation Method 2
resulting in gene modification at a target locus via nonhomologous end joining (NHEJ)-mediated insertions/deletions (indels) or homology-directed repair (HDR) based on an exogenously supplied oligonucleotide
Data Source
AI summary
Compositions and methods are provided for production of cells useful in regenerative therapies.